Endocyte's lead compound improves some results in ovarian cancer trial, but jury's still out

June 15, 2010 | Analyst Insight

Endocyte (see the April 20, 2010 LRTJ) recently announced interim results for its Phase II Ovarian Cancer study at the American Society of Clinical Oncology (ASCO) conference in Chicago, Illinois....

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978